Meeting
2021 ASCO Annual Meeting
IFN-α, IFN-γ, IL-2 combined with TNF-α for predicting efficacy of PD-1 inhibitors combination therapy in patients with solid cancers.
Authors
Penghui Xing
Department of Neurosurgery, Fourth Hospital of Hebei Medical University, Shijiazhuang, China
Penghui Xing , Jinyan Zhang , Rongfeng Liu , Junyan Wang , Ming Ma , Lixing Wang , Wenjing Jiao , Junguo Shao , Yuxiang Wang , Hongtao He , Baoen Shan , Jian Shi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
PD1/PD-L1 Inhibitor Combinations
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2584)
DOI
10.1200/JCO.2021.39.15_suppl.2584
Abstract #
2584
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Activity of CBT-501, a novel humanized anti-PD-1 antibody, in a humanized genetically engineered mouse model of colon carcinoma.
First Author: Qing Zhou
Poster
2024 ASCO Annual Meeting
First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced melanoma: Safety and efficacy results from a phase I study.
First Author: Yu Chen
Poster
2022 ASCO Annual Meeting
Trial in progress: A phase 1-2, first-in-human, open label, dose escalation and expansion study of AU-007, a monoclonal antibody that binds to IL-2 and inhibits IL-2Rα binding, in patients with advanced solid tumors.
First Author: James Robert Vasselli
Poster
2022 ASCO Annual Meeting
PRaG regimens (PD-1 inhibitor combined with radiotherapy and GM-CSF with or not IL-2) rechallenge for patients with acquiring resistance to PD-1/PD-L1 inhibitors in refractory advanced solid tumors.
First Author: Meiling Xu